Trevi Therapeutics announced the completion of enrollment in its Phase 2a RIVER trial for the treatment of refractory chronic cough (RCC). This milestone advances Haduvio, an investigational therapy for chronic cough.
Topline data from the RIVER trial is expected to be reported in the first quarter of 2025. The study is a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover trial designed to evaluate Haduvio's efficacy, safety, tolerability, and dosing.
The trial enrolled approximately 60 adult patients across sites in the United Kingdom and Canada. The primary endpoint is the mean change in 24-hour cough frequency, measured by an objective cough monitor.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.